Sorry, you need to enable JavaScript to visit this website.

LYRICA® (pregabalin) What is the therapeutic dose of LYRICA® in the management of neuropathic pain?

Pfizer recognizes the public concern in relation to COVID-19, which continues to evolve. Click here to learn how we are responding.
Pfizer reconnaît les préoccupations du grand public concernant la situation liée à la COVID-19, qui continue d'évoluer. Cliquez ici pour savoir comment nous avons réagi.

What is the therapeutic dose of LYRICA® in the management of neuropathic pain?

The dose range is 75 to 300 mg twice daily.

Careful dose titration to the highest tolerable dose is the most appropriate approach in clinical practice.

Treatment should be initiated at a dose of 75 mg BD.

Based on individual patient response and tolerability, the dosage may be increased to
150 mg BD after 3 to 7 days, and if needed, to a maximum dose of 300 mg BD after an additional 7-days.

Dosage modification is required in patients with renal impairment (see table below).

Creatinine Clearance
Total Pregabalin Daily dose*Dose Regimen
Starting dose
Maximum dose
> 60150600Two divided doses
30 - 6075300Single daily dose or two divided doses
15 - 3025-50150Single daily dose or two divided doses
<152575Single daily dose
Supplementary dosage following haemodialysis (mg)
 25100Single dose+

*Total daily (mg/day) should be divided as indicated by dose regimen to provide mg/dose
+Supplementary dose is a single additional dose

Adapted from the LYRICA Product Information

LYRICA may be taken with or without food.


For additional information, please search for response documents on the HOME page



  1. LYRICA® (pregabalin) Product Information. Pfizer Australia Pty Ltd.
  2. Freynhagen R, et al. Pain Pract. 2015; 15(1):47-57.

Tips and Tricks

Searching Tips
For more accurate search results, please ensure you enter at least two specific keywords
Haven't found what you are looking for?
Try entering additional or different clinical terms to refine your search. Or you can submit an enquiry online via the Send Medical Enquiry tab or contact Pfizer’s Medical Information Service on 1800 675 229.
Product Information
For a full list of Product Information documents, click on the Product Information tab.
Want to provide some feedback?
Complete the Pfizer Medical Information Website Survey to answer a few questions about your experience and satisfaction with the site.

Contact Pfizer Medical Information

Speak live with a Pfizer Medical Information professional
1800 675 229
Monday to Friday 9am – 5pm EST